 Home > Medical News > Latest Medical News > TOT BIOPHARM's Bevacizumab Injection Approved for Multiple New Indications

TOT BIOPHARM's Bevacizumab Injection Approved for Multiple New Indications

 Last Update: 2022-05-27
 Source: Internet
 Author: User

Tags

keytruda lung cancer

ovarian cancer cells

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On March 9, TOT BIOPHARM announced that three new supplementary application indications for bevacizumab injection Puxinting® filed by the company have been approved by the National Medical Products Administration (NMPA), namely: recurrent glioblastoma cell tumors, epithelial ovarian, fallopian tube or primary peritoneal cancer, and cervical cancer

Reference source: NMPA

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.